Tenapanor治疗便秘型肠易激综合征的26周安慰剂对照3期试验
T3MPO-2是一项随机双盲安慰剂对照3期试验,评估Tenapanor 50 mg每日两次治疗便秘型肠易激综合征(IBS-C)的长期疗效与安全性。共620例患者随机,593例纳入意向治疗分析,治疗26周。结果显示Tenapanor组6/12周联合应答率显著高于安慰剂组(36.5% vs 23.7%,P<0.001),腹泻是最常见不良事件,多为暂时性轻中度。
要点
- Tenapanor 50 mg每日两次治疗26周,IBS-C联合应答率显著优于安慰剂。
- 腹泻是最常见不良事件,多为暂时性轻中度,因腹泻停药率6.5%。
- Tenapanor可能成为IBS-C的潜在长期治疗选择。
核心结论
- Tenapanor 50 mg每日两次治疗26周可改善IBS-C症状,且总体耐受性良好,提供潜在新长期治疗选择。
研究设计与样本
- 随机双盲安慰剂对照3期试验(NCT02686138),IBS-C患者接受Tenapanor 50 mg每日两次或安慰剂每日两次治疗26周。
- 620例随机,593例(95.6%)纳入意向治疗分析(Tenapanor组293例,安慰剂组300例),481例(77.6%)完成26周治疗。
主要发现
- 意向治疗分析中,Tenapanor组6/12周联合应答率36.5%,安慰剂组23.7%,差异显著(P<0.001)。
- Tenapanor相比安慰剂显著改善腹部症状和IBS整体症状。
- 腹泻是最常见不良事件,通常为暂时性、轻至中度;因腹泻停药者Tenapanor组19例(6.5%),安慰剂组2例(0.7%)。
关键数值与推荐
- 主要终点为前12个治疗周中至少6周同时达到平均每周最严重腹痛较基线降低≥30.0%且每周完全自发排便次数较基线增加≥1次。
- 意向治疗分析集平均年龄45.4岁,女性占82.1%。
临床怎么用
- Tenapanor 50 mg每日两次可作为IBS-C的潜在长期治疗选项,需关注腹泻及因腹泻停药的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tenapanor is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3. This phase 3 trial assessed the long-term efficacy and safety of tenapanor 50 mg b.i.d. for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). METHODS: In this randomized double-blind study (ClinicalTrials.gov identifier: NCT02686138), patients with IBS-C received tenapanor 50 mg b.i.d. or placebo b.i.d. for 26 weeks. The primary endpoint was the proportion of patients who had a reduction of ≥30.0% in average weekly worst abdominal pain and an increase of ≥1 weekly complete spontaneous bowel movement from baseline, both in the same week, for ≥6 of the first 12 treatment weeks (6/12-week combined responder). RESULTS: Of the 620 randomized patients with IBS-C, 593 (95.6%) were included in the intention-to-treat analysis set (tenapanor: n = 293; placebo: n = 300) and 481 patients (77.6%) completed the 26-week treatment period. In the intention-to-treat analysis set (mean age: 45.4 years; 82.1% women), a significantly greater proportion of patients treated with tenapanor were 6/12-week combined responders than those treated with placebo (36.5% vs 23.7%; P < 0.001). Abdominal symptoms and global symptoms of IBS were significantly improved with tenapanor compared with placebo. Diarrhea, the most common adverse event, was typically transient and mild to moderate in severity. Diarrhea led to study drug discontinuation for 19 (6.5%) and 2 patients (0.7%) receiving tenapanor and placebo, respectively. DISCUSSION: Tenapanor 50 mg b.i.d. improved IBS-C symptoms over 26 weeks and was generally well tolerated, offering a potential new long-term treatment option for patients with IBS-C (see Visual abstract, Supplementary Digital Content 1, http://links.lww.com/AJG/B797).
引用
- Chey WD, Lembo AJ, Yang Y, et al. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2). Am J Gastroenterol. 2021. PMID: 33337659. doi:10.14309/ajg.0000000000001056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。